Literature DB >> 3527989

Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin.

J D Clements, F L Lyon, K L Lowe, A L Farrand, S el-Morshidy.   

Abstract

We used Salmonella enteritidis serotype dublin strain SL1438, a nonreverting, aromatic-dependent, histidine-requiring mutant, as a recipient for a recombinant plasmid coding for production of the nontoxic B subunit of the heat-labile Escherichia coli enterotoxin. The S. enteritidis derivative EL23 produced heat-labile enterotoxin subunit B that was indistinguishable from heat-labile enterotoxin subunit B produced by strains of E. coli or Salmonella typhi harboring the same plasmid. Mice immunized orally with strain EL23 developed progressively increasing mucosal and serum antibody responses to both heat-labile enterotoxin subunit B and to the lipopolysaccharide of the vaccine strain. The mucosal antibody response was shown to be immunoglobulin A specific and to be capable of neutralizing the biological activities of both E. coli heat-labile enterotoxin and cholera enterotoxin in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527989      PMCID: PMC260848          DOI: 10.1128/iai.53.3.685-692.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin.

Authors:  T Honda; R A Finkelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

2.  Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

3.  Studies on toxinogenesis in Vibrio cholerae. I. Isolation of mutants with altered toxinogenicity.

Authors:  R A Finkelstein; M L Vasil; R K Holmes
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

4.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants.

Authors:  J J Mekalanos; R J Collier; W R Romig
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

6.  Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture.

Authors:  D A Sack; R B Sack
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

7.  Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine.

Authors:  R H Gilman; R B Hornick; W E Woodard; H L DuPont; M J Snyder; M M Levine; J P Libonati
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

8.  Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

9.  Intracellular distribution of heat-labile enterotoxin in a clinical isolate of Escherichia coli.

Authors:  J D Clements; K L Lowe; L Bonham; S el-Morshidy
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

View more
  32 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 3.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

4.  Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.

Authors:  J X Bao; J D Clements
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Oral immunization of mice with a live recombinant Yersinia enterocolitica O:9 strain that produces the cholera toxin B subunit.

Authors:  M P Sory; P Hermand; J P Vaerman; G R Cornelis
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 6.  Oral vaccination.

Authors:  G Dougan; D Maskell; D O'Callaghan; S Chatfield; I Charles; C Hormaeche
Journal:  Antonie Van Leeuwenhoek       Date:  1988       Impact factor: 2.271

7.  Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity.

Authors:  E L Hohmann; C A Oletta; W P Loomis; S I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing.

Authors:  K Denich; P Börlin; P D O'Hanley; M Howard; A W Heath
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans.

Authors:  S Khan; S Chatfield; R Stratford; J Bedwell; M Bentley; S Sulsh; R Giemza; S Smith; E Bongard; C A Cosgrove; J Johnson; G Dougan; G E Griffin; J Makin; D J M Lewis
Journal:  Vaccine       Date:  2007-03-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.